Click on image to view larger version.
FIGURE 1. Time course of CLR and fitted monoexponential decay. (A) Patient was 75-y-old woman with insulinoma and hypertension who received 11.6 GBq of 90Y-DOTATOC, with estimated renal dose of 27.5 Gy. CLR loss was 26%/y (95% CI, 24.4%–27.5%), with ESRD at 5 y after first treatment. (B) Patient was 52-y-old man with papillary thyroid carcinoma who received 25.9 GBq of 177Lu-DOTATATE, with estimated renal dose of 23.3 Gy. CLR loss was 2.7%/y (95% CI, 0.2%–5.0%).
